Editas Medicine will host a virtual event to highlight initial clinical data from the RUBY trial of EDIT-301 for severe sickle cell disease
Published Medicine, Inc. CAMBRIDGE, Mass., Dec. 01 10, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the RUBY Phase 1/2 trial of EDIT-301, being developed for …